RESHAPE LIFESCIENCES INC (RSLS) Stock Price, Quote, News and Overview
NASDAQ:RSLS - Nasdaq - US76090R3093 - Common Stock - Currency: USD
RSLS Quote, Performance and Key Statistics
NASDAQ:RSLS (2/21/2025, 12:47:58 PM)
1.0987
-0.13 (-10.67%)
The current stock price of RSLS is 1.0987 USD. In the past month the price decreased by -71.46%. In the past year, price decreased by -86.23%.
RSLS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.9 | 234.12B | ||
| ISRG | INTUITIVE SURGICAL INC | 81.52 | 213.13B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.82 | 154.69B | ||
| SYK | STRYKER CORP | 31.56 | 146.64B | ||
| MDT | MEDTRONIC PLC | 16.86 | 115.44B | ||
| BDX | BECTON DICKINSON AND CO | 16.37 | 65.37B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.2 | 43.57B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.3 | 41.64B | ||
| IDXX | IDEXX LABORATORIES INC | 40.36 | 37.18B | ||
| DXCM | DEXCOM INC | 53.84 | 34.70B | ||
| RMD | RESMED INC | 26.14 | 33.93B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.41 | 23.89B |
Related stock screener links
About RSLS
Company Profile
ReShape Lifesciences Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in San Clemente, California and currently employs 31 full-time employees. The company went IPO on 2016-10-06. ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The firm offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Company Info
RESHAPE LIFESCIENCES INC
1001 Calle Amanecer
San Clemente CALIFORNIA 92673 US
CEO: Andrew Rasdal
Employees: 29
Company Website: https://www.reshapelifesciences.com/obalon/
Investor Relations: https://ir.reshapelifesciences.com/
Phone: 19494296680
RESHAPE LIFESCIENCES INC / RSLS FAQ
What is the stock price of RESHAPE LIFESCIENCES INC today?
The current stock price of RSLS is 1.0987 USD. The price decreased by -10.67% in the last trading session.
What is the ticker symbol for RESHAPE LIFESCIENCES INC stock?
The exchange symbol of RESHAPE LIFESCIENCES INC is RSLS and it is listed on the Nasdaq exchange.
On which exchange is RSLS stock listed?
RSLS stock is listed on the Nasdaq exchange.
What is RESHAPE LIFESCIENCES INC worth?
RESHAPE LIFESCIENCES INC (RSLS) has a market capitalization of 780.08K USD. This makes RSLS a Nano Cap stock.
How many employees does RESHAPE LIFESCIENCES INC have?
RESHAPE LIFESCIENCES INC (RSLS) currently has 29 employees.
Is RESHAPE LIFESCIENCES INC (RSLS) expected to grow?
The Revenue of RESHAPE LIFESCIENCES INC (RSLS) is expected to grow by 12.24% in the next year. Check the estimates tab for more information on the RSLS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RESHAPE LIFESCIENCES INC (RSLS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RSLS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RSLS, evaluating the profitability, health, valuation and growth aspects
- RESHAPE LIFESCIENCES INC (RSLS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RESHAPE LIFESCIENCES INC (RSLS) Sales and EPS estimates to see what analysts future expectations are.
- RESHAPE LIFESCIENCES INC (RSLS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RESHAPE LIFESCIENCES INC (RSLS) Insider and Institutional Ownership to learn about the owners and their transactions.
- RESHAPE LIFESCIENCES INC (RSLS) Stock Chart to make your own analysis
- RESHAPE LIFESCIENCES INC (RSLS) Latest news and press-releases to stay up to date.
Does RESHAPE LIFESCIENCES INC (RSLS) stock pay dividends?
RSLS does not pay a dividend.
When does RESHAPE LIFESCIENCES INC (RSLS) report earnings?
RESHAPE LIFESCIENCES INC (RSLS) will report earnings on 2025-03-31, after the market close.
What is the Price/Earnings (PE) ratio of RESHAPE LIFESCIENCES INC (RSLS)?
RESHAPE LIFESCIENCES INC (RSLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-205.92).
What is the Short Interest ratio of RESHAPE LIFESCIENCES INC (RSLS) stock?
The outstanding short interest for RESHAPE LIFESCIENCES INC (RSLS) is 3.47% of its float. Check the ownership tab for more information on the RSLS short interest.
RSLS Technical Analysis
RSLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RSLS. The financial health of RSLS is average, but there are quite some concerns on its profitability.
RSLS Financial Highlights
Over the last trailing twelve months RSLS reported a non-GAAP Earnings per Share(EPS) of -205.92. The EPS increased by 95.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.86% | ||
| ROE | -475.25% | ||
| Debt/Equity | 0 |
RSLS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to RSLS. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 99.78% and a revenue growth 12.24% for RSLS